Key points are not available for this paper at this time.
Population
A 13-year-old girl with Andersen-Tawil Syndrome
Comparison
Off-label treatment with acetazolamide
Design
Case report
Answers are grounded in this paper and cite their sources.
Acetazolamide may reduce paralysis episodes in pediatric ATS; hypothesis-generating and requires prospective trials before adoption.
We present a case report of a 13-year-old girl with Andersen-Tawil Syndrome (ATS), a rare genetic disorder which is characterized by dysmorphic features, ventricular arrhythmias, and frequent episodes of muscle paralysis that interfere with daily activities and social engagement. After the introduction of off-label treatment with acetazolamide periods without paralysis lengthened, our patient became more independent of the help of her parents and required a wheelchair less frequently, thus improving her social life. Based on our experience, we recommend a trial of acetazolamide in patients with ATS.
No takes yet. Share an insight, caveat, or question.
Žakelj et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: